REG - Allergy Therapeutics - Allergy Therapeutics – Result of GM

Allergy TherapeuticsAnnouncement

17/10/2022 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221017:nRSQ1398Da&default-theme=true

RNS Number : 1398D  Allergy Therapeutics PLC  17 October 2022

Allergy Therapeutics plc

 

("Allergy Therapeutics", "ATL", the "Company" or the "Group")

 

Result of GM

 

17 October 2022 Allergy Therapeutics (AIM: AGY), the fully integrated
specialty pharmaceutical company specialising in allergy immunotherapy,
announces that at the General Meeting ("GM") held today all resolutions were
duly passed.

 

Accordingly, the Company has conditionally raised total gross proceeds of
approximately £17,000,000 million in aggregate (before expenses) through the
Subscription and Debt Financing as described in the announcement date 29
September 2022. The Subscription and Debt Financing remain conditional on
Admission.

 

Admission

 

An application has been made for 35,000,000 New Ordinary Shares to be
admitted to trading on AIM. Admission of the New Ordinary Shares are expected
to occur at 8.00 a.m. on, or around, 19 October 2022. The New Ordinary Shares
will rank pari passu with the Existing Ordinary Shares.

 

Total Voting Rights

 

Following Admission of the New Ordinary Shares, the Company's issued ordinary
share capital will consist of 679,104,621 Ordinary Shares, carrying one vote
each. The Company does not currently hold any shares in treasury. Therefore,
the total number of voting rights in the Company following Admission will be
679,104,621. Shareholders may use this figure as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the issued share capital of the
Company, under the FCA's Disclosure Guidance and Transparency Rules.

 

Save as defined herein, capitalised terms have the same meaning as in the
Company's Subscription and Debt Financing announcement made by the Company on
29 September 2022.

 

- ENDS -

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon (Nominated Adviser and Broker)

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com (mailto:christina@sternir.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company
focussed on the treatment and diagnosis of allergic disorders, including
aluminium free immunotherapy vaccines that have the potential to cure disease.
The Group sells proprietary and third-party products from its subsidiaries in
nine major European countries and via distribution agreements in an additional
ten countries. Its broad pipeline of products in clinical development includes
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group, which
employs c.600 employees, is listed on the London Stock Exchange (AIM:AGY). For
more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMLDLFFLBLLFBE